Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer

Interim follow up results from a phase II study of neoadjuvant chemoembolization of resectable colorectal liver metastases (CRLM) with transcatheter hepatic therapy with irinotecan-eluting beads.

(2017) Robert Peter Jones et al.   JOURNAL OF CLINICAL ONCOLOGY

Induction of prolonged early G1arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1

(2013) David Chiron et al.   CELL CYCLE

Randomized Phase II, Double-Blind, Placebo-Controlled Study of Exemestane With or Without Entinostat in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Treatment With a Nonsteroidal Aromatase Inhibitor

(2013) Denise A. Yardley et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma

(2013) Mark A. Dickson et al.   JOURNAL OF CLINICAL ONCOLOGY

Cyclin dependent kinases in cancer

(2012) Miriam Canavese et al.   CANCER BIOLOGY & THERAPY

The CDK4/6 Inhibitor PD0332991 Reverses Epithelial Dysplasia Associated with Abnormal Activation of the Cyclin-CDK-Rb Pathway

(2012) M. C. Cabrera et al.   Cancer Prevention Research

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

(2012) A. Kathleen McClendon et al.   CELL CYCLE

CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, “fueling” tumor growth via paracrine interactions, without an increase in neo-angiogenesis

(2012) Claudia Capparelli et al.   CELL CYCLE

Killing cells by targeting mitosis

(2012) E Manchado et al.   CELL DEATH AND DIFFERENTIATION

Modification of the DNA Damage Response by Therapeutic CDK4/6 Inhibition

(2012) Jeffry L. Dean et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Multiple Roles of Cyclin-Dependent Kinase 4/6 Inhibitors in Cancer Therapy

(2012) Patrick J. Roberts et al.   JNCI-Journal of the National Cancer Institute

Estrogen receptor-dependent and independent mechanisms of breast cancer carcinogenesis

(2012) Wei Yue et al.   STEROIDS

The retinoblastoma family of proteins and their regulatory functions in the mammalian cell division cycle

(2012) Shauna A Henley et al.   Cell Division

On the molecular mechanisms of mitotic kinase activation

(2012) R. Bayliss et al.   Open Biology

G-protein-coupled estrogen receptor GPR30 and tamoxifen resistance in breast cancer

(2011) Atanas Ignatov et al.   BREAST CANCER RESEARCH AND TREATMENT

Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

(2011) G K Schwartz et al.   BRITISH JOURNAL OF CANCER

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Rb inactivation in cell cycle and cancer: The puzzle of highly regulated activating phosphorylation of CDK4 versus constitutively active CDK-activating kinase

(2011) Sabine Paternot et al.   CELL CYCLE

Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer

(2011) K. T. Flaherty et al.   CLINICAL CANCER RESEARCH

Killing the second messenger: targeting loss of cell cycle control in endocrine-resistant breast cancer

(2011) C. A. Lange et al.   ENDOCRINE-RELATED CANCER

Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer

(2011) C. Thangavel et al.   ENDOCRINE-RELATED CANCER

Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer

(2011) Todd W. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Breast Cancer in the United States: Current and Future Trends

(2011) W. F. Anderson et al.   JNCI-Journal of the National Cancer Institute

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

(2011) José Baselga et al.   NEW ENGLAND JOURNAL OF MEDICINE

Physiological Relevance of Cell Cycle Kinases

(2011) Marcos Malumbres   PHYSIOLOGICAL REVIEWS

ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer

(2011) T. W. Miller et al.   Cancer Discovery

RB-pathway disruption in breast cancer

(2010) Adam Ertel et al.   CELL CYCLE

Roscovitine, a selective CDK inhibitor, reduces the basal and estrogen-induced phosphorylation of ER-α in human ER-positive breast cancer cells

(2010) Józefa Węsierska-Gądek et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure

(2010) J L Dean et al.   ONCOGENE

High prevalence of retinoblastoma protein loss in triple-negative breast cancers and its association with a good prognosis in patients treated with adjuvant chemotherapy

(2009) D. Trere et al.   ANNALS OF ONCOLOGY

Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer

(2009) T. W. Miller et al.   CANCER RESEARCH

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

(2009) Stephen Johnston et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study

(2009) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Mammalian cell-cycle regulation: several Cdks, numerous cyclins and diverse compensatory mechanisms

(2009) A Satyanarayana et al.   ONCOGENE

Rb Depletion Results in Deregulation of E-Cadherin and Induction of Cellular Phenotypic Changes that Are Characteristic of the Epithelial-to-Mesenchymal Transition

(2008) Y. Arima et al.   CANCER RESEARCH

Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy

(2008) M. Rudas et al.   CLINICAL CANCER RESEARCH

G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells

(2008) Akira ICHIKAWA et al.   Human Cell